Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 What controls PTEN and what it controls (in prostate cancer).

× No keyword cloud information.

16 in total

1. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state.

Authors: H Murillo; H Huang; L J Schmidt; D I Smith; D J Tindall
Journal: Endocrinology Date: 2001-11 Impact factor: 4.736

Review 2. Pten inactivation and the emergence of androgen-independent prostate cancer.

Authors: Michael M Shen; Cory Abate-Shen
Journal: Cancer Res Date: 2007-07-15 Impact factor: 12.701

3. Characterization of MUC1 glycoprotein on prostate cancer for selection of targeting molecules.

Authors: Patricia A Burke; Jeffrey P Gregg; Brandon Bakhtiar; Laurel A Beckett; Gerald L Denardo; Huguette Albrecht; Ralph W De Vere White; Sally J De Nardo
Journal: Int J Oncol Date: 2006-07 Impact factor: 5.650

Review 4. Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients.

Authors: Gerhardt Attard; Johann S de Bono
Journal: Clin Cancer Res Date: 2011-06-15 Impact factor: 12.531

Review 5. PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer.

Authors: D J Mulholland; S Dedhar; H Wu; C C Nelson
Journal: Oncogene Date: 2006-01-19 Impact factor: 9.867

6. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage.

Authors: M E McMenamin; P Soung; S Perera; I Kaplan; M Loda; W R Sellers
Journal: Cancer Res Date: 1999-09-01 Impact factor: 12.701

7. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial.

Authors: Karen G Chee; Jeff Longmate; David I Quinn; Gurkamal Chatta; Jacek Pinski; Przemyslaw Twardowski; Chong-Xian Pan; Angelo Cambio; Christopher P Evans; David R Gandara; Primo N Lara
Journal: Clin Genitourin Cancer Date: 2007-12 Impact factor: 2.872

8. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival.

Authors: Y Wang; M Mikhailova; S Bose; C-X Pan; R W deVere White; P M Ghosh
Journal: Oncogene Date: 2008-09-08 Impact factor: 9.867

9. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability.

Authors: Ingo K Mellinghoff; Igor Vivanco; Andrew Kwon; Chris Tran; John Wongvipat; Charles L Sawyers
Journal: Cancer Cell Date: 2004-11 Impact factor: 31.743

10. Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation.

Authors: Roble Bedolla; Thomas J Prihoda; Jeffrey I Kreisberg; Shazli N Malik; Naveen K Krishnegowda; Dean A Troyer; Paramita M Ghosh
Journal: Clin Cancer Res Date: 2007-07-01 Impact factor: 12.531

1 in total

1. Biochemical and cellular evidence demonstrating AKT-1 as a binding partner for resveratrol targeting protein NQO2.

Authors: Tze-chen Hsieh; Chia-Yi Lin; Dylan John Bennett; Erxi Wu; Joseph M Wu
Journal: PLoS One Date: 2014-06-26 Impact factor: 3.240

1 in total